Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia

被引：0

作者：

Keyuan Zhang

Xiang Zhang

Yang Xu

Shengli Xue

Huiying Qiu

Xiaowen Tang

Yue Han

Suning Chen

Aining Sun

Yanming Zhang

Depei Wu

Ying Wang

机构：

[1] The First Affiliated Hospital of Soochow University,National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology

[2] Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology

[3] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health,Department of Hematology

[4] The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an,State Key Laboratory of Radiation Medicine and Protection

[5] Soochow University,undefined

来源：

Blood Cancer Journal | / 13卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Real-World Efficacy and Hematologic Toxicity of Azacitidine and Venetoclax in a Cohort of Elderly Patients Unfit for Intensive Chemotherapy With Newly Diagnosed Acute Myeloid Leukemia
Wysoglad, Hubert
Krawczyk, Katarzyna
Ochrem, Bogdan
Madry, Krzysztof
Drozd-Sokolowska, Joanna
Sacha, Tomasz
Basak, Grzegorz
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S294 - S294
[42] A retrospective comparison of abbreviated course "7+7" vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia
Bazinet, Alexandre
Dinardo, Courtney Denton
Arani, Naszrin
Bataller, Alex
Rausch, Caitlin R.
Maiti, Abhishek
Swaminathan, Mahesh
Daver, Naval Guastad
Kadia, Tapan M.
Ravandi-Kashani, Farhad
Kantarjian, Hagop M.
Chraibi, Samy
Decroocq, Justine
Pascal, Laurent
Lebon, Delphine
Bonnet, Sarah
Gauthier, Nicolas
Pages, Arnaud
De Botton, Stephane
Willekens, Christophe
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[43] Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia
Salhotra, Amandeep
Tsai, Ni-Chun
Zhang, Jianying
Ngo, Dat
Aribi, Ahmed
Sandhu, Karamjeet
Ball, Brian
Al-Malki, Monzr
Ali, Haris
Koller, Paul
Artz, Andrew
Forman, Stephen
Nakamura, Ryotaro
Stein, Anthony
Marcucci, Guido
Aldoss, Ibrahim
Pullarkat, Vinod
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (06) : E71 - E74
[44] Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia
Short, Nicholas J.
Wierzbowska, Agnieszka
Cluzeau, Thomas
Laribi, Kamel
Recher, Christian
Czyz, Jaroslaw
Ochrem, Bogdan
Ades, Lionel
Gallego-Hernanz, Maria Pilar
Heiblig, Mael
Audisio, Ernesta
Zarzycka, Ewa
Li, Shuli
Ferenc, Nicholas
Yeh, Tammie
Faller, Douglas V.
Sedarati, Farhad
Papayannidis, Cristina
LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 458 - 468
[45] Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax plus Hypomethylating Agent
Gangat, Naseema
Elbeih, Azeem
Ghosoun, Nour
Mccullough, Kristen
Aperna, Fnu
Johnson, Isla M.
Abdelmagid, Maymona
Al-Kali, Aref
Alkhateeb, Hassan B.
Begna, Kebede H.
Elliott, Michelle
Mangaonkar, Abhishek
Matin, Aasiya
Saliba, Antoine N.
Torghabeh, Mehrdad Hefazi
Litzow, Mark R.
Hogan, William
Shah, Mithun
Patnaik, Mrinal M.
Pardanani, Animesh
Badar, Talha
Murthy, Hemant
Foran, James
Palmer, Jeanne
Sproat, Lisa
Khera, Nandita
Yi, Cecilia Arana
Yates, Samuel
Sneider, Abigail
Dworkin, Emily
Patel, Anand A.
Bazinet, Alexandre
Senapati, Jayastu
Bataller, Alex
Dinardo, Courtney
Kadia, Tapan
Tefferi, Ayalew
AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (02) : 260 - 271
[46] A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study
Smith, B. Douglas
Lachowiez, Curtis A.
Ambinder, Alexander Joseph
Binder, Gary
Angiolillo, Anne
Vestin, Assaf
Paglia, Robert
Potluri, Ravi
Papademetriou, Eros
LeBlanc, Thomas W.
BLOOD, 2023, 142
[47] Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)
Arslan, Shukaib
Zhang, Jianying
Dhakal, Prajwal
Moran, Jenna A.
Naidoo, Nuthana
Story, Jennifer Lombardi
Pullarkat, Vinod A.
Stein, Anthony S.
Marcucci, Guido
Yaghmour, George
Bhatt, Vijaya R.
Fathi, Amir T.
Aldoss, Ibrahim
BLOOD, 2020, 136
[48] Venetoclax Combined with Hypomethylating Agents for Treatment-Naive B/Myeloid Mixed Phenotype Acute Leukemia
Wu, Di
Chen, Wenlan
Chen, Zhichao
Li, Qiubai
CASE REPORTS IN HEMATOLOGY, 2021, 2021
[49] Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax/hypomethylating agents
Kayser, Sabine
Sanber, Khaled
Marconi, Giovanni
Mattei, Agnese
Luskin, Marlise R.
Kelkar, Amar
Cerrano, Marco
Kristensen, Daniel Tuyet
Roug, Anne Stidsholt
Sartor, Chiara
Giglio, Fabio
Riva, Marta
Rizzo, Lorenzo
Saraceni, Francesco
Guerzoni, Selene
Lessi, Federica
Borlenghi, Erika
Levis, Mark J.
Schlenk, Richard F.
Jain, Tania
Papayannidis, Cristina
HAEMATOLOGICA, 2025, 110 (02) : 378 - 384
[50] Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents
Zainaldin, Carl
Arora, Sankalp
Bathini, Srilakshmi
Gupta, Udita
Pandya, Vishruti
Bae, Sejong
Worth, Sarah
Bachiashvili, Kimo
Bhatia, Ravi
Godby, Kelly
Jamy, Omer
Rangaraju, Sravanti
Diamond, Barry
Oliver, Josh D.
Salzman, Donna
Di Stasi, Antonio
Vachhani, Pankit
LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3245 - 3248

← 1 2 3 4 5 →